GlycoMimetics. has been granted a patent for methods and compositions utilizing E-selectin antagonists, including glycomimetic compounds, to treat cancers such as leukemia, lymphoma, and myeloma. The approach aims to inhibit cancer cell adhesion and metastasis, serving as an adjunct therapy to chemotherapy and radiotherapy. GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GlycoMimetics, Cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of June 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
E-selectin antagonists for cancer treatment and prevention
The granted patent US11987598B2 outlines a method for treating various types of cancer, specifically leukemia, lymphoma, and myeloma, through the administration of a compound of Formula (I) or its pharmaceutically acceptable salts. This treatment is designed to serve as an adjunct therapy alongside established treatments such as chemotherapy and radiotherapy. The claims detail the administration of the compound in various forms, including specific salts like sodium, potassium, and others, and emphasize the potential for combination therapies involving multiple chemotherapy agents, which may include alkylating agents, antimetabolites, anthracyclines, plant alkaloids, and topoisomerase inhibitors.
The patent further specifies the types of leukemia (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia) and lymphomas (e.g., non-Hodgkin lymphoma and Hodgkin lymphoma) that can be treated. It also highlights the possibility of administering the compound before, concurrently, or after chemotherapy or radiotherapy. The claims encompass a range of treatment combinations, including those involving two or more chemotherapy agents, thereby providing a comprehensive approach to cancer treatment that integrates the novel compound with existing therapeutic modalities.
To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
